Jacob Plieth — @oncinvestor $NUVL website vs #Jefferies25 schedule https://t.co/KnSvWsQ6TD↗
Nov 19
Jacob Plieth — I can't see $NUVL on the #Jefferies25 London agenda, so I presume they pulled out.↗
Nov 17
Jacob Plieth — @Abby10Smalls @AaronRosenblum5 38% by Recist 1.1, all confirmed, not sure if by BICR or not $NUVL https://t.co/OTLPdjxZXW↗
Nov 17
Jacob Plieth — $NUVL presses ahead in ALK, stock +10% despite waning data and liver tox worries. Via @ApexOnco -> https://t.co/pWOkE181mu↗
October 2025 · 2 mentions
Oct 22
Jacob Plieth — Who won #ESMO25 and who lost? Via @ApexOnco
https://t.co/EWzHIIH1Ck
$IOBT $CELC $RCUS $CGEM $IDYA $NUVL $AGEN $GILD $DSNKY $INCY $CATX $LPTX $OLMA $SMMT $AVBP $GMAB $EXEL $CGEN $Z…↗
Oct 20
Jacob Plieth — Good morning biotwitter! If you're catching up with #ESMO25 here's what we've published over the weekend https://t.co/lzhy6k4Raz
Stocks to watch this morning: $GMAB $CELC $IOBT $MR…↗
August 2025 · 2 mentions
Aug 29
Jacob Plieth — #WCLC25 press briefing schedule is out
Sat 6 Sep: two iza-bren studies $BMY
Sun 7 Sep: Harmoni $SMMT & Arros-1 $NUVL
Tue 9 Sep: $CADL↗
Aug 20
Jacob Plieth — #WCLC25 late-breaker & plenary preview, via @ApexOnco https://t.co/VJj3Bocr0A $SMMT $BMY $BNTX $NUVL $CGEM↗
June 2025 · 6 mentions
Jun 24
Jacob Plieth — And here's your handy $NUVL vs $NUVB X-trial comparison (note caveats) https://t.co/HgHxFZio6C↗
Jun 24
Jacob Plieth — $NUVL tries to match $NUVB, but zidesamtinib has lost important ground in the front line. @ApexOnco take on the Arros-1 update, plus filing plans -> https://t.co/JG83lbhPkq↗
Jun 24
Jacob Plieth — Today it's $NUVL's turn with its ROS1-selective inhibitor zidesamtinib. Arros-1 data out by PR at 6:30am ET, then investor call at 8am. $NUVB↗
Jun 12
Jacob Plieth — $NUVB -10%, mkt cap $670m
$NUVL +1%, mkt cap $5.5bn
Nov 17
Jacob Plieth — And here's why! $NUVL https://t.co/HjS5DoBWkl↗
Nov 17
Jacob Plieth — Also this from $NUVL (not sure if disclosed before): enhanced monitoring for transaminase elevations and prompt dose interventions have been implemented in the protocol for the ph3…↗
Nov 17
Jacob Plieth — ...and here are my quick comps: $NUVL Alkove-1 data, phase 1 vs pivotal stage https://t.co/OVveaViy1Q↗
Nov 17
Jacob Plieth — Here's the $NUVL comparison vs phase 1, from #ESMO24 https://t.co/dTTfAbZi52↗
Nov 17
Adam Feuerstein ✡️ — Nuvalent $NUVL sees success for its second genetically targeted lung cancer drug https://t.co/BN2gjd1qR7 via @matthewherper↗
Nov 17
Jacob Plieth — Also $NUVL presents at #Jefferies25 in London on Wednesday↗
Nov 17
Jacob Plieth — $NUVL reveals ORR from pivotal stage of Alkove-1 is 31%. That's lower than 38% cited in phase 1 stage, but need to delve into details.↗
Nov 17
Jacob Plieth — $NUVL neladalkib data from pivotal part of Alkove-1 in TKI pretreated ALK+ve NSCLC coming today at 6:30am ET↗
Jacob Plieth — @oncinvestor @BiotechObserver Meanwhile, this is what $NUVL claims for zidesamtinib https://t.co/UM18rwywwL↗
Jun 12
Jacob Plieth — $NUVB still claiming that Ibtrozi (taletrectinib) is a "next-generation Ros1 inhibitor", but this is what the FDA says: $NUVL https://t.co/dWd3WYf0cJ↗